Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page
- Check3 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedAdded Primary peritoneal carcinoma as a study condition and added the Genetic and Rare Diseases Information Center as a resource. Removed the government funding lapse notice and updated the page revision to v3.4.2.SummaryDifference0.6%

- Check38 days agoChange DetectedA site-wide notice regarding government funding and NIH Clinical Center operations was added. The page revision tag was updated to v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check45 days agoChange DetectedThe page adds a glossary display option and updates metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), replacing the previous wording (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check59 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing Revision: v3.3.3. This appears to be a backend version update with no changes to the study details or user interactions on the page.SummaryDifference0.1%

- Check81 days agoChange DetectedAdded Illinois locations under the Locations section. Revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.